Ratings BICO Group AB

Equities

BICO

SE0013647385

Real-time Estimate Cboe Europe Other stock markets 12:54:07 02/05/2024 pm IST			5-day change	1st Jan Change
47.41 ^SEK	+2.40%		-1.55%	-17.52%

18/04	BICO Group AB Announces the Appointment of Anders Fogelberg as Chief Commercial Officer, Effective June 13, 2024	CI
16/04	BICO Group AB Announces Gerry Mackay and Erik Gatenholm Decline Re-Election of the Board of Directors	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The company's share price in relation to its net book value makes it look relatively cheap.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

The company has insufficient levels of profitability.
The company is in debt and has limited leeway for investment
With an expected P/E ratio at 231.5 and 24.89 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
BICO GROUP AB	-17.52%	298M	C+
THERMO FISHER SCIENTIFIC	+8.33%	219B	B
DANAHER CORPORATION	+6.72%	183B	B-
INTUITIVE SURGICAL, INC.	+10.18%	132B	B-
BOSTON SCIENTIFIC CORPORATION	+24.91%	106B	A-
SIEMENS HEALTHINEERS AG	-1.10%	62.09B	A-
EDWARDS LIFESCIENCES CORPORATION	+10.56%	50.8B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+4.81%	50.88B	B+
AGILENT TECHNOLOGIES, INC.	-0.24%	40.64B	A
GE HEALTHCARE TECHNOLOGIES INC.	+1.22%	35.71B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes